Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY19 results · Jul–Sep 2018
Bliss GVS Pharma reported revenue from operations of ₹228.43 crore and net profit of ₹41.67 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 228.43 | — | — | 205.33 | +11.2% |
| Other income | 24.87 | — | — | 13.87 | +79.4% |
| Total income | 253.31 | — | — | 219.20 | +15.6% |
| Profit before tax | 62.79 | — | — | 51.04 | +23.0% |
| Net profit for the period | 41.67 | — | — | 38.98 | +6.9% |
| Attributable to shareholders of the company | 41.46 | — | — | 38.32 | +8.2% |
| EPS, basic (₹) | 4.02 | — | — | 3.72 | +8.1% |
| Net margin (%) | 18.2 | — | 19.0 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.97 | — | — | 104.84 | +14.4% |
| Other income | 24.01 | — | — | 13.14 | +82.7% |
| Total income | 143.98 | — | — | 117.98 | +22.0% |
| Profit before tax | 49.20 | — | — | 37.68 | +30.6% |
| Net profit for the period | 31.05 | — | — | 27.05 | +14.8% |
| EPS, basic (₹) | 3.01 | — | — | 2.62 | +14.9% |
| Net margin (%) | 25.9 | — | 25.8 |
Consolidated
- Filed with BSE
- 06 Nov 2018, 16:40 IST
- Board meeting
- 02 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2018, 16:40 IST
- Board meeting
- 02 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE